Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

EyeCyte Obtains $3M from Pfizer through Series A Round

  • EyeCyte secured a $3 million series A financing through an agreement with Pfizer. The backing will reportedly support the company into 2010. EyeCyte focuses on stem/progenitor cell-based ophthalmology R&D.

    According to this investment, Pfizer will become EyeCyte’s sole pharmaceutical partner and have an advisory and board role. Pfizer will also have right of first refusal for a buy-out of EyeCyte or its technologies.

    “We are very pleased with the terms of our collaboration and believe that Pfizer shares our goal of building a premier ophthalmology research and development organization with an emphasis on stem/progenitor cell based therapies,” remarks Mohammad A. El-Kalay, Ph.D., president and CEO, EyeCyte.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »